Ramalingam, S.S., Belani, C.P., Mack, P.C., Vokes, E.E., Longmate, J., Govindan, R., Koczywas, M., Ivy, S.P. and Gandara, D.R. (2010) Phase II Study of Cediranib [AZD 2171], an Inhibitor of the Vascular Endothelial Growth Factor Receptor, for Second-Line Therapy of Small Cell Lung Cancer [National Cancer Institute #7097]. Journal of Thoracic Oncology, 5, 1279-1284.
http://dx.doi.org/10.1097/JTO.0b013e3181e2fcb0

has been cited by the following article:

• TITLE: Missing the Target?—Targeted Therapy in Small Cell Lung Cancer

  AUTHORS: Karin R. Purshouse

  KEYWORDS: Oncology, Small Cell Lung Cancer, Targeted Therapy, Drug Development

  JOURNAL NAME: Advances in Lung Cancer, Vol.3 No.3, August 22, 2014

  ABSTRACT: Small cell lung cancer [SCLC] is a devastating form of cancer, with most patients harbouring extensive disease at diagnosis and survival of less than 5% at five years. Progress in novel therapies has been limited. This specialist review explores current targeted therapy options and potential areas of development.